The results, presented as an Oral Abstract at the Conference on Retroviruses and Opportunistic Infections (CROI) held virtually February 12...

The ICMR Director-General Balram Bhargava had said that molnupiravir has major safety concerns and has not been included in the national pr...

Generic molnupiravir will increase access in India and other low- and middle-income countries (LMICs), while simplifying current supply cha...

Molnupiravir has been given emergency use authorisation by the Drug Controller General of India (DCGI) for treatment of adult COVID-19 pati...

Merck Sharp & Dohme (MSD) on Friday said its COVID antiviral molnupiravir has cut the risk of hospitalization or death in Phase 3 clinical ...

The Drug Controller General of India had last week approved Merck and Ridgeback’s antiviral molnupiravir for the treatment of mild-to-moder...

The drug firm said it is able to manufacture the active pharmaceutical ingredient (API) as well as the formulation for Molnupiravir, and ha...

"This launch is yet another step in our endeavour to enable access to all treatments in COVID care. We continue to be guided by the power o...

Torrent Pharmaceuticals on Tuesday said it will launch MSD and Ridgeback's molnupiravir under the brand name Molnutor in India for the trea...

The USFDA also said the drug should be given for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or cl...

UK approved molnupiravir, the COVID antiviral developed by Merck and Ridgeback Therapeutics. Now, Pfizer has released results from trials o...

The analysis of latest data on efficacy is much less than the previous interim analysis announced by the company which was based on data fr...

The company said the Drugs Controller General of India (DCGI) is currently reviewing clinical data of molnupiravir for the treatment of COV...

Under the terms of the agreement, MPP will be permitted to further license non-exclusive sub-licences to manufacturers and diversify the ma...

The Indian bulk drugs manufacturer joins Divi's Laboratories Ltd as an API maker for Merck's experimental oral drug. Merck has separately e...

In a meeting held on October 4, both the companies said that they “they want to discontinue phase III trial in moderate Covid-19 patients a...

One promising drug that could improve things is molnupiravir, an antiviral that's moving into the final stages of testing in humans. Resear...